Rosacea is, at its core, an inflammatory condition. The redness, bumps, burning, and visible blood vessels that define rosacea all stem from an overactive immune and neurovascular response in the skin. While it’s sometimes mistaken for acne or simple blushing, rosacea involves a distinct chain of inflammatory events that can affect not just the face but potentially the whole body.
What Makes Rosacea Inflammatory
The inflammation in rosacea starts with the innate immune system, your body’s first line of defense against threats. In healthy skin, immune sensors called Toll-like receptors detect environmental changes like UV exposure, temperature shifts, or microbial activity, then trigger a controlled release of protective molecules. In rosacea, this response is amplified far beyond what’s needed.
One key player is cathelicidin, an antimicrobial peptide the skin normally produces in small amounts to fight infection. People with rosacea produce abnormally high levels of cathelicidin, and their skin also overproduces an enzyme (kallikrein 5) that processes cathelicidin into forms that are both inflammatory and vasoactive, meaning they dilate blood vessels. When researchers injected these cathelicidin fragments into mouse skin, the result was visible blood vessel dilation. In rabbit models, the same peptides triggered the growth of entirely new blood vessels. This helps explain both the persistent redness and the spider-like visible veins that characterize rosacea.
The cascade doesn’t stop there. These inflammatory cathelicidin fragments also recruit white blood cells to the skin, promote the breakdown of structural tissue, and stimulate the growth of new (and often unwanted) blood vessels. Reactive oxygen species, essentially unstable molecules that damage cells, are also elevated and help sustain the cycle of inflammation.
How Triggers Activate Inflammation
The flushing that rosacea patients experience isn’t just cosmetic. It’s driven by a neurovascular system that overreacts to everyday stimuli. Sensory channels called TRP channels sit on nerve endings, blood vessel cells, immune cells, and skin cells throughout the face. These channels respond to heat, emotional stress, spicy food, and other common rosacea triggers by flooding the area with signaling molecules.
When activated, TRP channels cause blood vessels to widen through the release of nitric oxide and prostaglandins, producing the characteristic flush. They also prompt nerve endings to release neuropeptides like substance P and CGRP, which bind to nearby immune cells, including mast cells, macrophages, and neutrophils, and instruct them to produce even more inflammatory mediators. This creates a feedback loop: triggers activate nerves, nerves activate immune cells, and immune cells release compounds that sensitize nerves further.
UV radiation deserves special mention. Sunlight doesn’t just cause flushing in the moment. It stimulates skin cells to produce excess cathelicidin, which then triggers mast cells to degranulate, releasing their stored inflammatory chemicals all at once. This is one reason sun exposure is consistently rated the most common rosacea trigger.
The Role of Skin Mites
Tiny mites called Demodex folliculorum live in the hair follicles of almost everyone’s face, typically at a density of less than 1 per square centimeter. In people with papulopustular rosacea (the type with red bumps and pus-filled lesions), that density jumps to roughly 12.8 per square centimeter, about 15 times the normal level. The mites themselves, and the bacteria they carry, are recognized by the skin’s immune sensors as threats, adding yet another trigger to the inflammatory cascade. This elevated mite density is specific to the bumpy, pustular form of rosacea and supports a pathogenic role for Demodex in that subtype.
Clinical Features Tied to Inflammation
The global ROSacea COnsensus panel identifies two diagnostic features of rosacea: persistent centrofacial redness (which may intensify periodically in response to triggers) and phymatous changes, the thickened, bulbous skin most commonly seen on the nose. Both are direct consequences of chronic inflammation. Persistent redness results from ongoing blood vessel dilation and new vessel growth. Phymatous changes represent the end result of long-term inflammation causing fibrosis and glandular overgrowth.
Major features include flushing (temporary redness with warmth, burning, or pain), papules and pustules, and telangiectasia (visible blood vessels in the central face). Minor features include burning or stinging sensations, skin that feels dry and rough, and facial swelling that can be soft or firm. Every one of these features traces back to the inflammatory and neurovascular processes described above. The panel notes that in darker skin tones (Fitzpatrick types V and VI), the redness may be harder to detect visually, which can delay diagnosis even though the underlying inflammation is the same.
How Treatments Target Inflammation
Because rosacea is fundamentally inflammatory, its most effective treatments work by interrupting the inflammatory cascade rather than killing bacteria. This distinction matters: even oral medications traditionally classified as antibiotics are prescribed at doses too low to have any antimicrobial effect.
Low-dose doxycycline, prescribed as a 40 mg modified-release capsule, stays below the concentration needed to kill bacteria in the bloodstream. Instead, it works as a pure anti-inflammatory agent. It modulates the cathelicidin pathway, reduces the activity of tissue-degrading enzymes, dampens neutrophil migration to the skin, and lowers reactive oxygen species and inflammatory signaling molecules like IL-6.
Topical treatments follow the same principle. Azelaic acid inhibits reactive oxygen species production in a dose-dependent manner by blocking a key enzyme on the surface of neutrophils (the white blood cells most responsible for generating damaging oxidants in rosacea skin). It’s particularly effective against the most reactive oxygen species and can even protect skin cells from UV-induced damage for up to 48 hours. Metronidazole works similarly, suppressing neutrophil-generated oxidants without affecting neutrophil movement or their ability to fight actual infections. Neither drug works by scavenging free radicals directly. Instead, both calm the immune cells that produce them.
Rosacea’s Connection to Systemic Inflammation
The inflammation in rosacea doesn’t necessarily stay confined to the face. In a large Brazilian multicenter study, 89% of rosacea patients reported at least one comorbidity. Nearly half had endocrine conditions like diabetes, obesity, or metabolic syndrome. About 31% had cardiovascular disease, with hypertension affecting roughly 30% and abnormal cholesterol levels in 15.5%. Gastrointestinal conditions appeared in about 28% of patients, and psychiatric conditions in 35%.
These associations likely reflect shared inflammatory pathways. The same elevated cathelicidins and pro-inflammatory cytokines that drive rosacea in the skin circulate systemically and contribute to oxidative stress throughout the body. Rosacea has been linked in broader research to cardiovascular, psychiatric, neurodegenerative, gastrointestinal, neurological, endocrine, and autoimmune diseases. This doesn’t mean rosacea causes these conditions, but it suggests that the chronic inflammation underlying rosacea is part of a wider pattern of immune dysregulation that can affect multiple organ systems over time.